March 22nd 2024
In an interview with Targeted Oncology, Julie Chang, MD, discussed the minimal residual disease-adapted study in patients with previously untreated mantle cell lymphoma and the key findings from the trial.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
ZUMA-18 Study Shows Brexu-cel's Therapeutic Potential in MCL
January 3rd 2024In an interview with Targeted Oncology, Andre Goy, MD, discussed the potential of brexucabtagene autoleucel for the treatment of patients with relapsed/refractory mantle cell lymphoma and how 2 studies provide support for use of the agent in this patient population.
Read More
Pirtobrutinib Shows Activity in Relapsed/Refractory MCL After Covalent BTK Inhibitor Therapy
December 12th 2023Pirtobrutinib demonstrated promising efficacy and a tolerable safety profile in heavily pretreated patients with relapsed/refractory mantle cell lymphoma who received prior therapy with a covalent BTK inhibitor.
Read More
Longer Follow-Up BRUIN Data Continues to Support Pirtobrutinib in MCL
September 5th 2023In an interview with Targeted Oncology, Nirav Shah, MD, discussed long-term follow-up results from the phase 1/2 BRUIN study and how the approval of pirtobrutinib has changed the MCL treatment landscape.
Read More
Zilovertamab With Ibrutinib Provides Durable Responses in MCL and CLL
August 9th 2023In an interview with Targeted Oncology, Hun Ju Lee, MD, discussed the encouraging responses shown with the combination of zilovertamab and ibrutinib in mantle cell lymphoma and chronic lymphocytic leukemia, and highlighted other studies making headway in the field.
Read More
Acalabrutinib Added to BR Demonstrates Tolerability and Promising Efficacy in MCL
June 9th 2023The addition of acalabrutinib to bendamustine and rituximab met tolerability and safety end points in a phase 1b trial, as well as promising efficacy results in patients with either treatment-naive or relapsed/refractory mantle cell lymphoma.
Read More
Tolerability of Zilovertamab and Ibrutinib in Phase 1/2 Trial of MCL
May 23rd 2023Hun Ju Lee, MD, discusses the early results of the dose finding and safety study of zilovertamab plus ibrutinib for patients with mantle cell lymphoma as well as chronic lymphocytic leukemia and marginal zone lymphoma.
Watch
Adding Lenalidomide to Rituximab Consolidation Shows No PFS Improvement in MCL
May 3rd 2023In an interview with Targeted Oncology, Mitchell Smith, MD, PhD, discussed what the findings from the ECOG-ACRIN E1411 trial in patients with mantle cell lymphoma means for the future of the space, and where research is heading.
Read More
Lisocabtagene Maraleucel Induces Significant Response in FL and MCL Populations
May 2nd 2023The TRANSCEND FL and TRANSCEND NHL 001 studies of lisocabtagene maraleucel met its primary end point of overall response rate and secondary end point of complete response rate in patients with follicular lymphoma and B-cell non-Hodgkin lymphoma.
Read More
Questions on Frontline or Later Use of Ibrutinib for MCL
April 6th 2023Mitchell Smith, MD, PhD, discusses how the updated results of the phase 2 ECOG-ACRIN E1411 trial of patients with previously untreated mantle cell lymphoma can be interpreted in context of data supporting the use of the Bruton’s tyrosine kinase inhibitor ibrutinib in this setting.
Watch
ASCT Shows No OS Effects vs Maintenance Rituximab After BR or R-CHOP in MCL
March 23rd 2023Clinical trials exploring regimens without ASCT consolidation in young patients with MCL are needed, and maintenance with rituximab should be considered for patients after first-line treatment with bendamustine plus rituximab and R-CHOP
Read More
Brexu-Cel Shows Comparable Outcomes With ZUMA-2 in Real-World MCL
February 14th 2023Patients treated with brexucabtagene autoleucel as standard of care in US Lymphoma CAR T Consortium centers responded to treatment consistently with the ZUMA-2 trial, showing real-world efficacy and safety as well as additional data on outcomes for patients with high-risk features and different bridging therapies.
Read More
FCS Clinical Trials Lead to FDA Approval of New Targeted Drug for Patients with Mantle Cell Lymphoma
February 14th 2023The FDA has approved the first non-covalent Bruton tyrosine kinase inhibitor for the treatment of relapsed or refractory mantle cell lymphoma in adult patients, based on clinical studies conducted with participation by Florida Cancer Specialists & Research Institute.
Read More